2026年5月1日，全球首款PROTAC蛋白降解剂vepdegestrant (商品名Veppanu)正式获美国FDA批准上市，用于治疗携带ESR1突变、既往内分泌治疗后疾病进展的ER阳性、HER2阴性晚期或转移性乳腺癌的患者。时隔25年，自2001年首篇PROTAC概念论文发表于PNAS，这项前沿生物医药技术终于从实验室落地临床，开启靶向蛋白降解疗法的全新时代。
本次研讨聚焦靶向蛋白降解领域的前沿科学研究与创新药物的早期研发和临床开发，围绕五大专题板块展开深度交流：1.小分子靶向蛋白降解药物发现；2.诱导邻近效应介导的新型降解机制与分子开发；3.临床阶段蛋白降解药物的研发进展与转化应用；4.膜蛋白靶向降解及溶酶体介导等新型降解技术探索；5.靶向蛋白降解相关的结构生物学、蛋白质组学等前沿研究与基础科学创新。大会汇聚数十位学术界与工业界权威讲者，系统呈现靶向蛋白降解领域的前沿科研成果、产业转化路径与临床开发进展。
On May 1, 2026, the world’s first PROTAC protein degrader, vepdegestrant (brand name: Veppanu), was officially approved by the U.S. FDA for the treatment of adult patients with ER‑positive, HER2‑negative advanced or metastatic breast cancer harboring ESR1 mutations, who have experienced disease progression following prior endocrine therapy. A quarter of a century has passed since the first conceptual paper on PROTAC was published in PNAS in 2001; this groundbreaking biomedical technology has now finally made the leap from the laboratory to clinical practice, ushering in a new era for targeted protein degradation therapeutics.
This symposium focuses on cutting‑edge scientific research in targeted protein degradation, as well as the early‑stage discovery and clinical development of innovative drugs in this field. It features in‑depth discussions across five thematic areas: (1) small‑molecule targeted protein degraders and drug discovery; (2) novel degradation mechanisms and molecular development mediated by induced proximity; (3) research advances and translational applications of clinical‑stage protein degraders; (4) exploration of emerging degradation technologies, including membrane protein targeting and lysosome‑mediated pathways; and (5) frontier research and foundational scientific innovations in structural biology, proteomics, and other related disciplines pertinent to targeted protein degradation. The conference brings together dozens of distinguished speakers from both academia and industry, and aims to systematically present the latest research achievements, industrial translation pathways, and clinical development progress across the entire targeted protein degradation landscape.
会议议程 PROGRAM
会议详情 CONFERENCE INFORMATION
组委会成员 ORGANIZERS
报告人 CONFIRMED SPEAKERS
会议注册 REGISTRATION
注册须知
Notice
1. 转账时请备注：TPD + [您的姓名]。
When making transfers, please include the following note: TPD + [Your Full Name].
2. 请于2026年11月7日前完成报名与缴费；现场报名仅提供电子版会议手册。
Please complete the registration and payment before November 7, 2026. Attendees registering on-site will be provided with only the electronic program.
3. 注册费电子发票将于会后15个工作日内发送至注册邮箱。
The electronic invoice for the registration fee will be sent to the registered email address within 15 working days after the symposium.
退款政策
Refund Policy
1. 所有退款申请将收取2%的手续费。
A 2% administrative fee will be charged for all refund transactions.
2. 2026年11月9日18:00（北京时间）后提交的退款申请将不予受理。
Refund requests submitted after 18:00 (GMT+8) on November 9, 2026 will not be processed.
墙报环节 POSTER SESSION
本次会议设有墙报展示环节，我们诚邀您投稿并参与墙报展示（特别鼓励展示最新研究进展或未发表课题）。会议将根据研究成果的原创性、重要性及演讲（展示）效果，评选出优秀海报奖若干名。
会议住宿 ACCOMMODATION
本次会议不统一安排住宿，参会代表可自行联系附近酒店。
1. 深圳光明天安云谷逸衡酒店
EVEN Hotels Shenzhen Guangming Cloud Park, an IHG Hotel.
2. 中大学人苑酒店
SYSU Academic Vila,Shenzhen Campus
3. 深圳光明中集行政公寓酒店
Guangming CIMC Executive Apartments Hotel
会议咨询 CONTACT
关于SMART Symposia
SMART Symposia是由深圳医学科学院主办的系列国际学术会议，旨在为全球生物医学研究人员搭建一个促进跨学科合作与交流的平台。在这里，不同领域的思想将碰撞出创新火花，前沿研究成果得以分享，共同推动生物医学领域的发展与进步。